{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T21:06:02Z","timestamp":1761426362383,"version":"build-2065373602"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Curcumin, a pharmacological agent found in turmeric\u2019s rhizome, has been studied for its various therapeutic properties. However, its clinical development is hindered by its instability and low solubility in water, resulting in inadequate oral bioavailability. Two potential curcumin analogs, 2,5-bis(4\u2019-hydroxy-3\u2019,5\u2019-dimethoxybenylidene)cyclopentanone (PGV-5) and 2,6-bis(4\u2019-hydroxy-3\u2019,5\u2019-dimethoxybenylidene)cyclohexanone (HGV-5), are being developed to address this issue and enhance their therapeutic efficacy. The study aims to screen novel curcumin analog compounds by integrating in silico assessment of ADME properties, acute toxicity studies, and computational analysis. PGV-5 and HGV-5 are classified as Global Harmonized System of Classification and Labeling of Chemicals (GHS) class 4 and class 5, respectively, in acute toxicity assessment, as they cause histopathological changes in the heart and lungs. Their ADME profile indicates they serve as effective P-glycoprotein (P-gp) inhibitors, making them potential candidates for development as anti-multidrug resistance agents, particularly in cancer cells. Molecular docking on P-gp revealed significant inhibitory capability relative to curcumin, exhibiting comparable binding characteristics to the native ligand, as evidenced by superior docking scores. Subsequent molecular dynamics simulations confirmed the stable interaction of both compounds with P-gp, with HGV-5 showing the most favorable binding free energy. Target gene mapping revealed several pivotal targets including AKT1, STAT3, EGFR, and NF-\u03baB1. These findings suggest that PGV-5 and HGV-5 merit further research as agents against multidrug-resistant in cancer, regardless of their toxicity profiles. Further confirmation of their effects requires more laboratory studies and clinical trials.<\/jats:p>","DOI":"10.1038\/s41598-025-02858-3","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:45:58Z","timestamp":1761036358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated molecular and ADME-toxicity profiling identifies PGV-5 and HGV-5 as potential agents to counteract multidrug-resistant (MDR) cancer"],"prefix":"10.1038","volume":"15","author":[{"family":"Ritmaleni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalina Diani Prima","family":"Anargya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najla","family":"Alivia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajona","family":"Marbun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Retno","family":"Murwanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranti Kamila","family":"Habibie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"2858_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szak\u00e1cs","year":"2006","unstructured":"Szak\u00e1cs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. & Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219\u2013234 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2858_CR2","first-page":"349","volume":"5","author":"M Liscovitch","year":"2002","unstructured":"Liscovitch, M. & Lavie, Y. Cancer multidrug resistance: A review of recent drug discovery research. IDrugs 5, 349\u2013355 (2002).","journal-title":"IDrugs"},{"key":"2858_CR3","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1021\/cr9000226","volume":"109","author":"PDW Eckford","year":"2009","unstructured":"Eckford, P. D. W. & Sharom, F. J. ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 109, 2989\u20133011 (2009).","journal-title":"Chem. Rev."},{"key":"2858_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0928-0987(00)00114-7","volume":"11","author":"R Krishna","year":"2000","unstructured":"Krishna, R. & Mayer, L. D. Multidrug resistance (MDR) in cancer. Eur. J. Pharm. Sci. 11, 265\u2013283 (2000).","journal-title":"Eur. J. Pharm. Sci."},{"key":"2858_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bcp.2011.10.004","volume":"83","author":"A Palmeira","year":"2012","unstructured":"Palmeira, A. et al. Dual inhibitors of P-glycoprotein and tumor cell growth: (Re)discovering thioxanthones. Biochem. Pharmacol. 83, 57\u201368 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"2858_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1749-8546-3-11","volume":"3","author":"H Itokawa","year":"2008","unstructured":"Itokawa, H., Shi, Q., Akiyama, T., Morris-Natschke, S. L. & Lee, K. H. Recent advances in the investigation of curcuminoids. Chin. Med. 3, 11 (2008).","journal-title":"Chin. Med."},{"key":"2858_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.tifs.2005.08.006","volume":"16","author":"GK Jayaprakasha","year":"2005","unstructured":"Jayaprakasha, G. K., Mohan Rao, J., Sakariah, K. K. & L. & Chemistry and biological activities of C. longa. Trends Food Sci. Technol. 16, 533\u2013548 (2005).","journal-title":"Trends Food Sci. Technol."},{"key":"2858_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.biocel.2008.06.010","volume":"41","author":"BB Aggarwal","year":"2009","unstructured":"Aggarwal, B. B. & Harikumar, K. B. Potential therapeutic effects of Curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell. Biol. 41, 40\u201359 (2009).","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"2858_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-2952(02)01224-8","volume":"64","author":"S Anuchapreeda","year":"2002","unstructured":"Anuchapreeda, S., Leechanachai, P., Smith, M. M., Ambudkar, S. V. & Limtrakul, P. Modulation of P-glycoprotein expression and function by Curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol. 64, 573\u2013582 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"2858_CR10","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.bcp.2004.07.009","volume":"68","author":"W Chearwae","year":"2004","unstructured":"Chearwae, W., Anuchapreeda, S., Nandigama, K., Ambudkar, S. V. & Limtrakul, P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by Curcumin I, II, and III purified from turmeric powder. Biochem. Pharmacol. 68, 2043\u20132052 (2004).","journal-title":"Biochem. Pharmacol."},{"key":"2858_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.semcancer.2017.06.010","volume":"46","author":"MC Bonferoni","year":"2017","unstructured":"Bonferoni, M. C., Rossi, S., Sandri, G. & Ferrari, F. Nanoparticle formulations to enhance tumor targeting of poorly soluble polyphenols with potential anticancer properties. Semin. Cancer Biol. 46, 205\u2013214 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"2858_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.foodres.2018.03.048","volume":"108","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Pluronics modified liposomes for Curcumin encapsulation: Sustained release, stability and bioaccessibility. Food Res. Int. 108, 246\u2013253 (2018).","journal-title":"Food Res. Int."},{"key":"2858_CR13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/mp700113r","volume":"4","author":"P Anand","year":"2007","unstructured":"Anand, P., Kunnumakkara, A. B., Newman, R. A. & Aggarwal, B. B. Bioavailability of Curcumin: Problems and promises. Mol. Pharm. 4, 807\u2013818 (2007).","journal-title":"Mol. Pharm."},{"key":"2858_CR14","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1016\/j.bmc.2008.02.012","volume":"16","author":"Y Um","year":"2008","unstructured":"Um, Y. et al. Synthesis of Curcumin mimics with multidrug resistance reversal activities. Bioorg. Med. Chem. 16, 3608\u20133615 (2008).","journal-title":"Bioorg. Med. Chem."},{"key":"2858_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.bcp.2014.12.012","volume":"93","author":"JL Revalde","year":"2015","unstructured":"Revalde, J. L., Li, Y., Hawkins, B. C., Rosengren, R. J. & Paxton, J. W. Heterocyclic cyclohexanone monocarbonyl analogs of Curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance. Biochem. Pharmacol. 93, 305\u2013317 (2015).","journal-title":"Biochem. Pharmacol."},{"key":"2858_CR16","unstructured":"Reksohadiprodjo, M. S. et al. Derivatives of benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and therapeutic uses thereof. (2004)."},{"key":"2858_CR17","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.13005\/ojc\/330503","volume":"33","author":"Y Eryanti","year":"2017","unstructured":"Eryanti, Y. et al. Synthesis, structure-activity relationship, Docking and molecular dynamic simulation of Curcumin analogues against HL-60 for anti cancer agents (Leukemia). Orient. J. Chem. 33, 2164\u20132172 (2017).","journal-title":"Orient. J. Chem."},{"key":"2858_CR18","doi-asserted-by":"publisher","first-page":"W422","DOI":"10.1093\/nar\/gkae236","volume":"52","author":"L Fu","year":"2024","unstructured":"Fu, L. et al. ADMETlab 3.0: An updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. Nucleic Acids Res. 52, W422\u2013W431 (2024).","journal-title":"Nucleic Acids Res."},{"key":"2858_CR19","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.29303\/jppipa.v9i10.5482","volume":"9","author":"A Lubis","year":"2023","unstructured":"Lubis, A., Wardhani, F. M., Lubis, A. T. & Tandanu, E. Cerebral histopathology in acute toxicity test of Curcuma Zedoria. Jurnal Penelitian Pendidikan IPA 9, 8368\u20138375 (2023).","journal-title":"Jurnal Penelitian Pendidikan IPA"},{"key":"2858_CR20","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.2174\/0929867325666171129121924","volume":"26","author":"S Vilar","year":"2019","unstructured":"Vilar, S., Sobarzo-S\u00e1nchez, E. & Uriarte, E. In Silico prediction of p-glycoprotein binding: Insights from molecular Docking studies. Curr. Med. Chem. 26, 1746\u20131760 (2019).","journal-title":"Curr. Med. Chem."},{"key":"2858_CR21","doi-asserted-by":"publisher","unstructured":"Test No. 420: Acute Oral Toxicity - Fixed Dose Procedure. OECD, (2002). https:\/\/doi.org\/10.1787\/9789264070943-en","DOI":"10.1787\/9789264070943-en"},{"key":"2858_CR22","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2174\/156802608786786624","volume":"8","author":"S Vilar","year":"2008","unstructured":"Vilar, S., Cozza, G. & Moro, S. Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery. Curr. Top. Med. Chem. 8, 1555\u20131572 (2008).","journal-title":"Curr. Top. Med. Chem."},{"key":"2858_CR23","doi-asserted-by":"publisher","first-page":"D464","DOI":"10.1093\/nar\/gky1004","volume":"47","author":"SK Burley","year":"2019","unstructured":"Burley, S. K. et al. RCSB protein data bank: Biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy. Nucleic Acids Res. 47, D464\u2013D474 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2858_CR24","doi-asserted-by":"crossref","unstructured":"Safran, M. et al. GeneCards Version 3: The human gene integrator. Database baq020\u2013baq020. (2010).","DOI":"10.1093\/database\/baq020"},{"key":"2858_CR25","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina, A., Michielin, O., Zoete, V. & SwissTargetPrediction Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 47, W357\u2013W364 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2858_CR26","doi-asserted-by":"publisher","first-page":"W726","DOI":"10.1093\/nar\/gkac297","volume":"50","author":"K Gallo","year":"2022","unstructured":"Gallo, K., Goede, A., Preissner, R. & Gohlke, B. O. SuperPred 3.0: Drug classification and target prediction\u2014A machine learning approach. Nucleic Acids Res. 50, W726\u2013W731 (2022).","journal-title":"Nucleic Acids Res."},{"key":"2858_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12859-015-0611-3","volume":"16","author":"H Heberle","year":"2015","unstructured":"Heberle, H. et al. A web-based tool for the analysis of sets through Venn diagrams. BMC Bioinform. 16, 169 (2015).","journal-title":"BMC Bioinform."},{"key":"2858_CR28","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk, D. et al. The STRING database in 2023: Protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638\u2013D646 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2858_CR29","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"2858_CR30","doi-asserted-by":"publisher","first-page":"W199","DOI":"10.1093\/nar\/gkz401","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 47, W199\u2013W205 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2858_CR31","doi-asserted-by":"publisher","unstructured":"Tsaioun, K. Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods. ALTEX 343\u2013358. https:\/\/doi.org\/10.14573\/altex.1610101 (2016).","DOI":"10.14573\/altex.1610101"},{"key":"2858_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/2230-973X.96921","volume":"2","author":"S Sareen","year":"2012","unstructured":"Sareen, S., Joseph, L. & Mathew, G. Improvement in solubility of poor water-soluble drugs by solid dispersion. Int. J. Pharm. Investig. 2, 12 (2012).","journal-title":"Int. J. Pharm. Investig."},{"key":"2858_CR33","doi-asserted-by":"crossref","unstructured":"Gupta, D., Bhatia, D., Dave, V., Sutariya, V. & Varghese Gupta, S. Salts of therapeutic agents: Chemical, physicochemical, and biological considerations. Molecules 23, 1719 (2018).","DOI":"10.3390\/molecules23071719"},{"key":"2858_CR34","doi-asserted-by":"crossref","unstructured":"Bhalani, D. V., Nutan, B., Kumar, A. & Singh Chandel, A. K. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines 10, 2055 (2022).","DOI":"10.3390\/biomedicines10092055"},{"key":"2858_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski, C. A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 1, 337\u2013341 (2004).","journal-title":"Drug Discov. Today Technol."},{"key":"2858_CR36","doi-asserted-by":"crossref","unstructured":"Ursu, O., Rayan, A., Goldblum, A. & Oprea T. I. Understanding drug-likeness. WIREs Comput. Mol. Sci. 1, 760\u2013781 (2011).","DOI":"10.1002\/wcms.52"},{"key":"2858_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/17460441.2012.648612","volume":"7","author":"WP Walters","year":"2012","unstructured":"Walters, W. P. Going further than Lipinski\u2019s rule in drug design. Expert Opin. Drug Discov. 7, 99\u2013107 (2012).","journal-title":"Expert Opin. Drug Discov."},{"key":"2858_CR38","doi-asserted-by":"publisher","first-page":"5560","DOI":"10.1016\/j.bmcl.2009.08.045","volume":"19","author":"TW Johnson","year":"2009","unstructured":"Johnson, T. W., Dress, K. R. & Edwards, M. Using the golden triangle to optimize clearance and oral absorption. Bioorg. Med. Chem. Lett. 19, 5560\u20135564 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2858_CR39","doi-asserted-by":"publisher","first-page":"10925","DOI":"10.3390\/ijms222010925","volume":"22","author":"T Kosugi","year":"2021","unstructured":"Kosugi, T. & Ohue, M. Quantitative estimate index for early-stage screening of compounds targeting protein-protein interactions. Int. J. Mol. Sci. 22, 10925 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2858_CR40","doi-asserted-by":"crossref","unstructured":"Li, B. et al. DrugMetric: Quantitative drug-likeness scoring based on chemical space distance. Brief Bioinform. 25 (2024).","DOI":"10.1093\/bib\/bbae321"},{"key":"2858_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13321-024-00800-9","volume":"16","author":"Y Gu","year":"2024","unstructured":"Gu, Y. et al. DBPP-predictor: A novel strategy for prediction of chemical drug-likeness based on property profiles. J. Cheminform. 16, 4 (2024).","journal-title":"J. Cheminform"},{"key":"2858_CR42","doi-asserted-by":"crossref","unstructured":"Ahmad, I. et al. Computational pharmacology and computational chemistry of 4-hydroxyisoleucine: Physicochemical, pharmacokinetic, and DFT-based approaches. Front. Chem. 11 (2023).","DOI":"10.3389\/fchem.2023.1145974"},{"key":"2858_CR43","doi-asserted-by":"publisher","first-page":"S335","DOI":"10.3233\/JAD-200185","volume":"82","author":"J Lakey-Beitia","year":"2021","unstructured":"Lakey-Beitia, J., Burillo, A. M., La Penna, G., Hegde, M. L. & Rao, K. S. Polyphenols as potential metal chelation compounds against Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 82, S335\u2013S357 (2021).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"2858_CR44","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.xphs.2019.02.005","volume":"108","author":"B Feng","year":"2019","unstructured":"Feng, B. et al. Validation of human MDR1-MDCK and BCRP-MDCK cell lines to improve the prediction of brain penetration. J. Pharm. Sci. 108, 2476\u20132483 (2019).","journal-title":"J. Pharm. Sci."},{"key":"2858_CR45","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s41598-018-19325-x","volume":"8","author":"AK Nanayakkara","year":"2018","unstructured":"Nanayakkara, A. K. et al. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Sci. Rep. 8, 967 (2018).","journal-title":"Sci. Rep."},{"key":"2858_CR46","doi-asserted-by":"publisher","unstructured":"Cohen, L. H. & Nicoll-Griffith, D. A. Plasma protein binding methods in drug discovery and development: Bioanalysis. in Encyclopedia of Drug Metabolism and Interactions 1\u201318 (Wiley, 2012). https:\/\/doi.org\/10.1002\/9780470921920.edm114.","DOI":"10.1002\/9780470921920.edm114"},{"key":"2858_CR47","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2174\/156802611794480918","volume":"11","author":"X Liu","year":"2011","unstructured":"Liu, X., Chen, C. & Hop, E. C. A. Do we need to optimize plasma protein and tissue binding in drug discovery? Curr. Top. Med. Chem. 11, 450\u2013466 (2011).","journal-title":"Curr. Top. Med. Chem."},{"key":"2858_CR48","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1208\/s12248-009-9102-7","volume":"11","author":"A Grover","year":"2009","unstructured":"Grover, A. & Benet, L. Z. Effects of drug transporters on volume of distribution. AAPS J. 11, 250\u2013261 (2009).","journal-title":"AAPS J."},{"key":"2858_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11481-006-9025-3","volume":"1","author":"Y Persidsky","year":"2006","unstructured":"Persidsky, Y., Ramirez, S. H., Haorah, J. & Kanmogne, G. D. Blood\u2013brain barrier: Structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 1, 223\u2013236 (2006).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"2858_CR50","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1021\/acs.jmedchem.7b00969","volume":"61","author":"DA Smith","year":"2018","unstructured":"Smith, D. A., Beaumont, K., Maurer, T. S. & Di, L. Relevance of half-life in drug design. J. Med. Chem. 61, 4273\u20134282 (2018).","journal-title":"J. Med. Chem."},{"key":"2858_CR51","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.yrtph.2007.11.009","volume":"50","author":"S Robinson","year":"2008","unstructured":"Robinson, S. et al. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regul. Toxicol. Pharmacol. 50, 345\u2013352 (2008).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"2858_CR52","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3109\/10837450.2012.734516","volume":"18","author":"I Kadiyala","year":"2013","unstructured":"Kadiyala, I. & Tan, E. Formulation approaches in mitigating toxicity of orally administrated drugs. Pharm. Dev. Technol. 18, 305\u2013312 (2013).","journal-title":"Pharm. Dev. Technol."},{"key":"2858_CR53","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/ph17040539","volume":"17","author":"AA Nevskaya","year":"2024","unstructured":"Nevskaya, A. A. et al. Nature-inspired 1-Phenylpyrrolo[2,1-a]isoquinoline scaffold for novel antiproliferative agents circumventing P-glycoprotein-dependent multidrug resistance. Pharmaceuticals 17, 539 (2024).","journal-title":"Pharmaceuticals"},{"key":"2858_CR54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejps.2018.06.022","volume":"122","author":"S Jain","year":"2018","unstructured":"Jain, S., Grandits, M. & Ecker, G. F. Interspecies comparison of putative ligand binding sites of human, rat and mouse P-glycoprotein. Eur. J. Pharm. Sci. 122, 134\u2013143 (2018).","journal-title":"Eur. J. Pharm. Sci."},{"key":"2858_CR55","doi-asserted-by":"publisher","first-page":"7972","DOI":"10.1038\/s41598-017-08062-2","volume":"7","author":"SB Syed","year":"2017","unstructured":"Syed, S. B. et al. Targeting P-glycoprotein: Investigation of Piperine analogs for overcoming drug resistance in cancer. Sci. Rep. 7, 7972 (2017).","journal-title":"Sci. Rep."},{"key":"2858_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.11648\/j.ajbls.20241203.12","volume":"12","author":"N Kumbhar","year":"2024","unstructured":"Kumbhar, N., Khan, N., Bavi, R., Barage, S. & Khan, A. Reversal of P-glycoprotein mediated multidrug resistance in MCF-7\/R cancer cells by Esculetin derivatives: Experimental and MD simulation studies. Am. J. Biomed. Life Sci. 12, 30\u201348 (2024).","journal-title":"Am. J. Biomed. Life Sci."},{"key":"2858_CR57","doi-asserted-by":"crossref","unstructured":"Tang, X., Cao, J., Bi, H. & Feng, J. Effect of Curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901\/VCR. Acta Pharmacol. Sin. 26, 1009\u20131016 (2005).","DOI":"10.1111\/j.1745-7254.2005.00149.x"},{"key":"2858_CR58","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6061\/clinics\/2013(05)18","volume":"68","author":"WD Lu","year":"2013","unstructured":"Lu, W. D., Qin, Y., Yang, C., Li, L. & Fu, Z. X. Effect of Curcumin on human colon cancer multidrug resistance in vitro and in vivo. Clinics 68, 694\u2013701 (2013).","journal-title":"Clinics"},{"key":"2858_CR59","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.canlet.2007.10.003","volume":"259","author":"BH Choi","year":"2008","unstructured":"Choi, B. H., Kim, C. G., Lim, Y., Shin, S. Y. & Lee, Y. H. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K\/Akt\/NF\u03baB pathway. Cancer Lett. 259, 111\u2013118 (2008).","journal-title":"Cancer Lett."},{"key":"2858_CR60","doi-asserted-by":"crossref","unstructured":"Follit, C. A., Brewer, F. K., Wise, J. G. & Vogel, P. D. In Silico identified targeted inhibitors of P-glycoprotein overcome multidrug resistance in human cancer cells in culture. Pharmacol. Res. Perspect. 3, (2015).","DOI":"10.1002\/prp2.170"},{"key":"2858_CR61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13020-023-00853-2","volume":"18","author":"L Li","year":"2023","unstructured":"Li, L. et al. Network pharmacology: A bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine. Chin. Med. 18, 146 (2023).","journal-title":"Chin. Med."},{"key":"2858_CR62","doi-asserted-by":"publisher","first-page":"e024583","DOI":"10.1136\/bmjopen-2018-024583","volume":"9","author":"YS Peng","year":"2019","unstructured":"Peng, Y. S. et al. Incidence and relative risk for developing cancers in women with gestational diabetes mellitus: A nationwide cohort study in Taiwan. BMJ Open. 9, e024583 (2019).","journal-title":"BMJ Open."},{"key":"2858_CR63","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.53328","author":"E Slouha","year":"2024","unstructured":"Slouha, E. et al. The relationship between gestational diabetes and the risk of cancer: A systematic review. Cureus https:\/\/doi.org\/10.7759\/cureus.53328 (2024).","journal-title":"Cureus"},{"key":"2858_CR64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha, J. H., Chan, L. C., Li, C. W., Hsu, J. L. & Hung, M. C. Mechanisms controlling PD-L1 expression in cancer. Mol. Cell. 76, 359\u2013370 (2019).","journal-title":"Mol. Cell."},{"key":"2858_CR65","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/BS9.0000000000000149","volume":"5","author":"YJ Zhou","year":"2023","unstructured":"Zhou, Y. J. et al. PD-L1: Expression regulation. Blood Sci. 5, 77\u201391 (2023).","journal-title":"Blood Sci."},{"key":"2858_CR66","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee, P. & Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 9, 52 (2017).","journal-title":"Cancers (Basel)"},{"key":"2858_CR67","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.3390\/cancers13112748","volume":"13","author":"ML Uribe","year":"2021","unstructured":"Uribe, M. L., Marrocco, I. & Yarden, Y. EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. Cancers (Basel) 13, 2748 (2021).","journal-title":"Cancers (Basel)"},{"key":"2858_CR68","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/febs.14809","volume":"286","author":"C Plattner","year":"2019","unstructured":"Plattner, C. & Hackl, H. Modeling therapy resistance via the <\u2009scp\u2009>\u2009egfr\u2009signaling pathway. FEBS J. 286, 1284\u20131286 (2019).","journal-title":"FEBS J."},{"key":"2858_CR69","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41419-018-1034-7","volume":"9","author":"R Ali","year":"2018","unstructured":"Ali, R., Brown, W., Purdy, S. C., Davisson, V. J. & Wendt, M. K. Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand. Cell. Death Dis. 9, 976 (2018).","journal-title":"Cell. Death Dis."},{"key":"2858_CR70","doi-asserted-by":"crossref","unstructured":"Kaidanovich-Beilin, O. & Woodgett, J. R. GSK-3: Functional insights from cell biology and animal models. Front Mol. Neurosci. 4 (2011).","DOI":"10.3389\/fnmol.2011.00040"},{"key":"2858_CR71","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1089\/ars.2010.3419","volume":"14","author":"KE van der Vos","year":"2011","unstructured":"van der Vos, K. E. & Coffer, P. J. The extending network of FOXO transcriptional target genes. Antioxid. Redox Signal. 14, 579\u2013592 (2011).","journal-title":"Antioxid. Redox Signal."},{"key":"2858_CR72","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-biophys-083012-130338","volume":"42","author":"J Napetschnig","year":"2013","unstructured":"Napetschnig, J. & Wu, H. Molecular basis of NF-\u03baB signaling. Annu. Rev. Biophys. 42, 443\u2013468 (2013).","journal-title":"Annu. Rev. Biophys."},{"key":"2858_CR73","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.semcancer.2020.03.016","volume":"80","author":"CD Mohan","year":"2022","unstructured":"Mohan, C. D. et al. Targeting STAT3 signaling pathway in cancer by agents derived from mother nature. Semin Cancer Biol. 80, 157\u2013182 (2022).","journal-title":"Semin Cancer Biol."},{"key":"2858_CR74","doi-asserted-by":"crossref","unstructured":"Chang, N. S., To, K. K., Liou, Y. C., Li, Y. J. & Editorial The role of STAT3 signaling pathway in tumor progression. Front. Oncol. 13, (2023).","DOI":"10.3389\/fonc.2023.1151862"},{"key":"2858_CR75","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","volume":"32","author":"B Wingelhofer","year":"2018","unstructured":"Wingelhofer, B. et al. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia 32, 1713\u20131726 (2018).","journal-title":"Leukemia"},{"key":"2858_CR76","doi-asserted-by":"crossref","unstructured":"Seelig, A. P-glycoprotein: One mechanism, many tasks and the consequences for pharmacotherapy of cancers. Front. Oncol. 10 (2020).","DOI":"10.3389\/fonc.2020.576559"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02858-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02858-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02858-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T21:02:07Z","timestamp":1761426127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02858-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2858"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02858-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36515"}}